Logo

argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy

Share this

argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy

Shots:

  • The US FDA has granted approval to the company’s Vyvgart Hytrulo (QW, 30-to-90 second, SC injection) co-formulated with Enhanze (rHuPH20) for treating chronic inflammatory demyelinating polyneuropathy (CIDP)
  • The approval was supported by the data from (ADHERE) trial investigating the safety and efficacy of Vyvgart Hytrulo (SC) vs PBO for treating CIDP adults (n=322)
  • The trial depicted improvements in mobility, function and strength among 69% (221/322) of participants and reached its 1EP showing lower relapse risk by 61% with 99% of them joining ADHERE open-label extension study

Ref: Argenx | Image: Argenx

Related News:- argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions